| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/APT.14033 |
| P698 | PubMed publication ID | 28474826 |
| P50 | author | John F. Dillon | Q38545342 |
| P2093 | author name string | M H Miller | |
| K E Clare | |||
| P2860 | cites work | Management of hepatocellular carcinoma: An update | Q27860530 |
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. | Q38933901 | ||
| Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. | Q39030388 | ||
| Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma | Q45275265 | ||
| Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century | Q58218199 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1469-1470 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Editorial: sorafenib toxicity, a biomarker of effect? | |
| P478 | volume | 45 |
| Q57301434 | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives | cites work | P2860 |
Search more.